Chapter title |
Targeting TCTP with Sertraline and Thioridazine in Cancer Treatment
|
---|---|
Chapter number | 15 |
Book title |
TCTP/tpt1 - Remodeling Signaling from Stem Cell to Disease
|
Published in |
Results and problems in cell differentiation, January 2017
|
DOI | 10.1007/978-3-319-67591-6_15 |
Pubmed ID | |
Book ISBNs |
978-3-31-967590-9, 978-3-31-967591-6
|
Authors |
Robert Amson, Christian Auclair, Fabrice André, Judith Karp, Adam Telerman, Amson, Robert, Auclair, Christian, André, Fabrice, Karp, Judith, Telerman, Adam |
Abstract |
We have initially demonstrated in knocking down experiments that decreasing TCTP in cancer cells leads in some tissues to cell death while in others to a complete reorganization of the tumor into architectural structures reminiscent of normal ones. Based on these experiments and a series of other findings confirming the key role of TCTP in cancer, it became important to find pharmacological compounds to inhibit its function, and this became for us a priority. In the present text, we explain in detail the experiments that were performed and the perspectives of sertraline in cancer treatment, as this became today a reality with a clinical study that started in collaboration with Columbia University and Johns Hopkins University. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 5 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 2 | 40% |
Student > Ph. D. Student | 1 | 20% |
Unknown | 2 | 40% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 20% |
Immunology and Microbiology | 1 | 20% |
Medicine and Dentistry | 1 | 20% |
Unknown | 2 | 40% |